Rhodes Pharmaceuticals L.P.
Records under this name other than the patents Rhodes Pharmaceuticals L.P. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 6 patents it holds.
Back to Rhodes Pharmaceuticals L.P.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,571,392 | Systems and Methods for Increasing Stability of Dronabinol Compositions Held by another company In force · High confidence | In force | High confidence | |
| US 9,861,628 | Buprenorphine Wafer for Drug Substitution Therapy Lapsed on the fee record Ended Jan 9, 2026 · High confidence | Lapsed on the fee record | Ended Jan 9, 2026 | High confidence |
| US 9,763,931 | Buprenorphine-Wafer for Drug Substitution Therapy Lapsed on the fee record Ended Sep 19, 2025 · High confidence | Lapsed on the fee record | Ended Sep 19, 2025 | High confidence |
| US 8,580,310 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations Term ended Term ended Apr 12, 2022 · USPTO record | Term ended | Term ended Apr 12, 2022 | USPTO record |
| US 6,589,960 | Hydromorphone and Hydrocodone Compositions and Methods for Their Synthesis Term ended Term ended Nov 9, 2020 · Medium confidence | Term ended | Term ended Nov 9, 2020 | Medium confidence |
| US 6,419,960 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations Term ended Term ended Dec 16, 2019 · USPTO record | Term ended | Term ended Dec 16, 2019 | USPTO record |
| US 6,673,367 | Controlled/modified release oral methylphenidate formulations Term ended Term ended Dec 16, 2019 · USPTO record | Term ended | Term ended Dec 16, 2019 | USPTO record |
| US 7,083,808 | Controlled/modified release oral methylphenidate formulations Term ended Term ended Dec 16, 2019 · USPTO record | Term ended | Term ended Dec 16, 2019 | USPTO record |
| US 7,247,318 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations Term ended Ended no later than Dec 16, 2019 · USPTO record | Term ended | Ended no later than Dec 16, 2019 | USPTO record |
| US 7,438,930 | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations Term ended Ended no later than Dec 16, 2019 · USPTO record | Term ended | Ended no later than Dec 16, 2019 | USPTO record |